04:52 PM EDT, 08/12/2024 (MT Newswires) -- Astria Therapeutics ( ATXS ) reported a Q2 loss late Monday of $0.43 per diluted share, compared with a loss of $0.45 a year earlier.

Four analysts polled by Capital IQ expected a loss of $0.40 per share.

As expected, no revenue for the quarter ended June 30 was reported.

As of June 30, the company said it had $354.7 million in cash, cash equivalents, and short-term investments that it projects will fund operations into mid-2027.